HRS-4508 + trastuzumab + capecitabine

HRS-4508 + trastuzumab + capecitabine is an experimental **combination regimen** under investigation for the treatment of advanced or metastatic solid tumors, particularly in HER2-positive cancers. **HRS-4508** is a small molecule chemical drug developed by Jiangsu Hengrui Medicine that is in Phase 1/2 clinical trials for solid tumors, including non-small cell lung cancer and potentially other malignancies[7][1][3][5]. **Trastuzumab** is a recombinant humanized monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (**HER2/ERBB2**), used for HER2-positive cancers such as breast and gastric cancer. **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), a small molecule antimetabolite interfering with DNA synthesis, used as chemotherapy for various cancers. The combination aims to provide synergistic anti-tumor effects by targeting HER2-positive tumor cells through antibody-mediated inhibition, cytotoxic chemotherapy, and additional novel mechanisms via HRS-4508.